The Medical Letter on Drugs and Therapeutics
Brinzolamide/Brimonidine (Simbrinza) for Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brinzolamide/Brimonidine (Simbrinza) for Glaucoma
The FDA has approved Simbrinza (Alcon), an ophthalmic combination of the carbonic anhydrase inhibitor brinzolamide and the selective alpha2-adrenergic receptor agonist brimonidine, for reduction of intraocular pressure (IOP) in patients with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Brinzolamide/Brimonidine (Simbrinza) for Glaucoma
Article code: 1421a
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.